News Organogenesis Holdings Inc.

Equities

ORGO

US68621F1021

Real-time Estimate Cboe BZX Other stock markets 01:12:07 2024-05-03 pm EDT			5-day change	1st Jan Change
2.565 ^USD	+3.01%		+8.30%	-37.78%

May. 02	Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis	CI
Feb. 29	Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu® for Knee Osteoarthritis	May. 02	AQ
Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis	May. 02	CI
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024	Apr. 16	AQ
Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case	Apr. 03	AQ
Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Organogenesis: Q4 Earnings Snapshot	Feb. 29	AQ
Organogenesis Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q4 Revenue $99.7M, vs. Street Est of $109.1M	Feb. 29	MT
Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance	Feb. 29	AQ
Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024	Feb. 29	CI
Organogenesis Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference	Feb. 12	AQ
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 29, 2024	Feb. 08	AQ
Organogenesis Holdings Insider Sold Shares Worth $940,860, According to a Recent SEC Filing	Jan. 11	MT
BTIG Raises Price Target on Organogenesis Holdings to $6 From $4, Keeps Buy Rating	Dec. 27	MT
HippoFi Hires World's Top Regenerative Therapy Expert, Dr. Gail Naughton, to Drive Commercialization Plans of its Proprietary Technologies	Dec. 12	AQ
ORGANOGENESIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Organogenesis Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	Dec. 06	BU
Morgan Stanley Adjusts Price Target on Organogenesis to $3.50 From $3, Maintains Equalweight Rating	Nov. 14	MT
Organogenesis: Q3 Earnings Snapshot	Nov. 09	AQ
Transcript : Organogenesis Holdings Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Organogenesis Holdings Inc.

Equities

ORGO

US68621F1021

Summary

Filters